Abstract: Objective:To study the clinical significance of serum soluble E-selectin (sE-selectin) in diagnosis and treat -ment of gastric cancer.Methods:Serum E-selectin was detected with ELISA in 200 cases of gastric cancer, 45cases of be-nign gastric diseases and 40healthy controls. The changes in serum sE-selectin level of 140 patients with gastric cancer were analyzed before and after surgery, and the positive ratio of sE-selectin was compared with that of CEA, CA199 and CA724 in patients with gastric cancer. Results: The level of serum sE-selectin in patients with gastric cancer was 69.12±18.19ng/mL, higher than that in those with benign diseases ( 19.47± 7.88)ng/mL and healthy controls ( 15.85± 5.27)ng/mL. The differences were significant ( P<0.01). The level of serum sE-selectin was correlated with clinical stage and hepatic me -tastasis in gastric cancer patients, but was not correlated with focal location and histological grade (P>0.05). The positive rate of serum sE-selectin in cases with hepatic metastasis was higher than that in those without hepatic metastasis ( P<0.01). The level of serum sE-selectin in patients with gastric cancer declined significantly at one month after surgery. The positive rate of serum sE-selectin in patients with gastric cancer was much higher than that of other digestive tumor mark-ers (CEA, CA199 , and CA 724 , P<0.01). Conclusion:sE-selectin may be a valuable marker for early diagnosis and progno -sis of gastric cancer.